The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

Discover how nail health is a crucial indicator of overall wellness. Learn about what your nails reveal about nutritional ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

A recent research letter reveals a strong connection between the consumption of ultra-processed foods and psoriasis flare-ups ...

Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

A new study shows that the US is still behind in controlling the price of prescription drugs. One doctor explains why America ...

Oprah also touted the brand in her Favorite Things List.

Eating diets high in ultra-processed foods such as cereal bars, flavored yogurts, and fast food may make it more likely to ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

Recent findings from a new study have revealed that heavy ultraprocessed foods intakes, such as that by sodas and frozen ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) ...